Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes.

Trial Profile

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Amisulpride (Primary) ; Aripiprazole (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PECANS
  • Most Recent Events

    • 25 May 2016 Status changed from active, no longer recruiting to completed.
    • 19 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 12 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top